TY - JOUR
T1 - Immunoglobulin G4-related disease and idiopathic multicentric Castleman's disease
T2 - Confusable immune-mediated disorders
AU - Sasaki, Takanori
AU - Akiyama, Mitsuhiro
AU - Kaneko, Yuko
AU - Takeuchi, Tsutomu
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - IgG4-related disease (IgG4-RD) and idiopathic multicentric Castleman's disease (iMCD) are both rare systemic immune-mediated disorders. However, the pathogenesis differs markedly between the two diseases and differing therapeutic strategies are adopted: IgG4-RD is treated using a moderate dose of glucocorticoids or rituximab, while iMCD therapy involves an IL-6-targeted approach. Nonetheless, some clinical features of IgG4-RD and iMCD overlap, so differential diagnosis is sometimes difficult, even though the classification and diagnostic criteria of the diseases require careful exclusion of the other. The key findings in IgG4-RD are high IgG4:IgG ratio, allergic features and germinal centre expansion involving T follicular helper cells, while iMCD involves polyclonal antibody production (high IgA and IgM levels), sheet-like mature plasma cell proliferation and inflammatory features driven by IL-6. The distribution of organ involvement also provides important clues in both diseases. Particular attention should be given to differential diagnosis using combined clinical and/or pathological findings, because single features cannot distinguish IgG4-RD from iMCD. In the present review, we discuss the similarities and differences between IgG4-RD and iMCD, as well as how to distinguish the two diseases.
AB - IgG4-related disease (IgG4-RD) and idiopathic multicentric Castleman's disease (iMCD) are both rare systemic immune-mediated disorders. However, the pathogenesis differs markedly between the two diseases and differing therapeutic strategies are adopted: IgG4-RD is treated using a moderate dose of glucocorticoids or rituximab, while iMCD therapy involves an IL-6-targeted approach. Nonetheless, some clinical features of IgG4-RD and iMCD overlap, so differential diagnosis is sometimes difficult, even though the classification and diagnostic criteria of the diseases require careful exclusion of the other. The key findings in IgG4-RD are high IgG4:IgG ratio, allergic features and germinal centre expansion involving T follicular helper cells, while iMCD involves polyclonal antibody production (high IgA and IgM levels), sheet-like mature plasma cell proliferation and inflammatory features driven by IL-6. The distribution of organ involvement also provides important clues in both diseases. Particular attention should be given to differential diagnosis using combined clinical and/or pathological findings, because single features cannot distinguish IgG4-RD from iMCD. In the present review, we discuss the similarities and differences between IgG4-RD and iMCD, as well as how to distinguish the two diseases.
KW - Castleman's disease
KW - IgG4-related disease
KW - biomarkers
KW - pathogenesis
UR - http://www.scopus.com/inward/record.url?scp=85124434018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124434018&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/keab634
DO - 10.1093/rheumatology/keab634
M3 - Review article
C2 - 34363463
AN - SCOPUS:85124434018
SN - 1462-0324
VL - 61
SP - 490
EP - 501
JO - Rheumatology and Rehabilitation
JF - Rheumatology and Rehabilitation
IS - 2
ER -